Original Article Purpose Primary effusion lymphoma (PEL) is a type of body cavity-based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden. Materials and Methods We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea. Results Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival. Conclusion PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.
|Number of pages||11|
|Journal||Cancer Research and Treatment|
|Publication status||Published - 2019|
Bibliographical noteFunding Information:
This work was supported by a grant from the National Research Foundation of Korea for the Cellular Heterogeneity Research Center (NRF-2016R1A5A1011974), funded by the Ministry of Science, ICT & Future planning, Republic of Korea. The authors thank the Consortium for Improving Survival of Lymphoma for their efforts in coordinating the study. This manuscript has been edited by native English-speaking experts associated with BioScience Writers LLC, Houston, TX, USA.
© 2020 Termedia Publishing House Ltd.. All rights reserved.
All Science Journal Classification (ASJC) codes
- Cancer Research